Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
2 reports, 2 independent
Updated Sep 11
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Ionis Pharmaceuticals is successfully treating Alexander disease using its drug Zanvastro.Sub-event
FDA grants approval for Ionis's Zanvastro for Alexander disease.1 source
Ionis seeks FDA approval for Alexander disease treatments and announces partnerships with AstraZeneca and Roche.1 source
Keep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
- FDA
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.